Jazz Pharmaceuticals PLC (JAZZ) Now Covered by Goldman Sachs Group, Inc. (The)
Equities researchers at Goldman Sachs Group, Inc. (The) started coverage on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report issued on Thursday. The brokerage set a “neutral” rating and a $165.00 price target on the specialty pharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price target would suggest a potential upside of 12.82% from the stock’s previous close.
A number of other research analysts have also recently issued reports on JAZZ. Mizuho dropped their target price on shares of Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating for the company in a report on Wednesday, May 31st. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a report on Tuesday, June 6th. Cowen and Company reaffirmed an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $182.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, BMO Capital Markets increased their target price on shares of Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $180.91.
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.27% during trading on Thursday, hitting $146.25. The company had a trading volume of 308,632 shares. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The stock’s 50-day moving average is $148.82 and its 200 day moving average is $150.52. The firm has a market capitalization of $8.78 billion, a P/E ratio of 22.53 and a beta of 1.13.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the company earned $2.67 earnings per share. Equities research analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/30/jazz-pharmaceuticals-plc-jazz-now-covered-by-goldman-sachs-group-inc-the.html.
In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $154.97, for a total transaction of $30,994.00. The disclosure for this sale can be found here. Insiders sold a total of 8,297 shares of company stock valued at $1,279,417 over the last ninety days. Company insiders own 4.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Intl Fcstone Inc. acquired a new position in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $230,000. Toronto Dominion Bank boosted its holdings in shares of Jazz Pharmaceuticals PLC by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $433,000. GRATRY & Co LLC boosted its holdings in shares of Jazz Pharmaceuticals PLC by 121.6% in the 2nd quarter. GRATRY & Co LLC now owns 17,040 shares of the specialty pharmaceutical company’s stock valued at $2,650,000 after buying an additional 9,350 shares during the period. Finally, Verition Fund Management LLC acquired a new position in shares of Jazz Pharmaceuticals PLC in the 2nd quarter valued at about $1,959,000. 88.24% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.